A Phase 1, Multicenter, Open-Label, Dose Finding Study of CC-96673 in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma
MD Anderson Study Status
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B, monotherapy dose expansion.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials: